Correlation Engine 2.0
Clear Search sequence regions


  • anti apoptosis (1)
  • cancer (4)
  • empower (1)
  • growth factor (1)
  • humans (1)
  • integrins (3)
  • metastasis (5)
  • receptors (1)
  • signal (2)
  • tumour (1)
  • Sizes of these terms reflect their relevance to your search.

    Resistance to therapeutic treatment and metastatic progression jointly determine a fatal outcome of cancer. Cancer metastasis and therapeutic resistance are traditionally studied as separate fields using non-overlapping strategies. However, emerging evidence, including from in vivo imaging and in vitro organotypic culture, now suggests that both programmes cooperate and reinforce each other in the invasion niche and persist upon metastatic evasion. As a consequence, cancer cell subpopulations exhibiting metastatic invasion undergo multistep reprogramming that - beyond migration signalling - supports repair programmes, anti-apoptosis processes, metabolic adaptation, stemness and survival. Shared metastasis and therapy resistance signalling are mediated by multiple mechanisms, such as engagement of integrins and other context receptors, cell-cell communication, stress responses and metabolic reprogramming, which cooperate with effects elicited by autocrine and paracrine chemokine and growth factor cues present in the activated tumour microenvironment. These signals empower metastatic cells to cope with therapeutic assault and survive. Identifying nodes shared in metastasis and therapy resistance signalling networks should offer new opportunities to improve anticancer therapy beyond current strategies, to eliminate both nodular lesions and cells in metastatic transit. © 2022. Springer Nature Limited.

    Citation

    Felix Weiss, Douglas Lauffenburger, Peter Friedl. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nature reviews. Cancer. 2022 Mar;22(3):157-173

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35013601

    View Full Text